Genzyme, a Sanofi Company
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Genzyme, a Sanofi Company sits in the top decile of US sponsors by registered trial count (#154 of 15,742 sponsors by registered trial count).
Genzyme, a Sanofi Company: 196 sponsored US clinical trials, 4 recruiting.
Genzyme, a Sanofi Company sponsors 196 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 159 completed. 65 of these trials are in Phase 3-4 (later-stage) and 114 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Glycogen Storage Disease Type II (GSD-II), with 5 trials.
Top-decile sponsor footprint
Genzyme, a Sanofi Company ranks in the top decile of sponsors by registered trial count (#154 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
159 of 188 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
196 total, page 1 of 4
Pompe Pregnancy Sub-Registry
NCT00567073
Pompe Disease Registry Protocol
NCT00231400
Fabry Disease Registry & Pregnancy Sub-registry
NCT00196742
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
NCT00358943
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B
NCT03974113
Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX
NCT03754790
A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa
NCT03019406
Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension
NCT02843035
A Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, and Safety of Venglustat in Late-onset GM2
NCT04221451
Study of Lademirsen (SAR339375) in Patients With Alport Syndrome
NCT02855268
Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada
NCT03784898
Effect of Venglustat in Patients With Renal Impairment
NCT03687554
A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients
NCT03523728
A Study of the Safety, Tolerability, and Pharmacokinetics of Orally Administered Venglustat and Itraconazole in Healthy Adult Male Participants
NCT06421714
A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis
NCT03549871
A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors
NCT03417245
A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors
NCT03417102
A Study of RG-012 in Subjects With Alport Syndrome
NCT03373786
A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation
NCT02906020
Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease
NCT02782741
Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency
NCT02004691
An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B
NCT02554773
LEMTRADA Pregnancy Registry in Multiple Sclerosis
NCT03774914
A Study of the Effects of Hepatic Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate
NCT02536911
Evaluation of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-Naïve Adult Male Patients With Fabry Disease
NCT02489344
Safety, Tolerability, PK, and Efficacy Evaluation of Repeat Ascending Doses of Olipudase Alfa in Pediatric Patients <18 Years of Age With Acid Sphingomyelinase Deficiency
NCT02292654
Taste Evaluation of Different Liquid Formulations With Eliglustat
NCT02422654
Alglucosidase Alfa Pompe Safety Sub-Registry
NCT01710813
Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839
NCT02306811
Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409
NCT02255656
Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease
NCT01410890
Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry Disease
NCT02228460
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
NCT02136862
Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
NCT02222948
Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis
NCT02201108
Avalglucosidase Alfa Extension Study
NCT02032524
A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency
NCT02004704
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
NCT01876784
Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients.
NCT01898364
A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
NCT01839526
Tolerability and Safety Study of Recombinant Human Acid Sphingomyelinase in Acid Sphingomyelinase Deficiency Patients
NCT01722526
A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Genz-682452 in Healthy Volunteers
NCT01710826
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
NCT01618708
Safety, Tolerability and Pharmacokinetics of Genz-682452 in Healthy Men
NCT01674036
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
NCT01665391
A Noninferiority Study of Alglucosidase Alfa Manufactured at the 160 L and 4000 L Scales in Treatment Naïve Patients With Infantile-Onset Pompe Disease
NCT01597596
Study to Evaluate the Effect of Eliglustat on the Pharmacokinetics, Safety and Tolerability of Metoprolol in Healthy Adults
NCT01659944
An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease
NCT01574326
A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta
NCT01650779
Pompe Lactation Sub-Registry
NCT00566878
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 48 |
| Phase 2 | 66 |
| Phase 3 | 40 |
| Phase 4 | 25 |
Therapeutic Areas
What is open in the Genzyme, a Sanofi Company pipeline
4 recruiting of 196 indexed (2% open); 159 completed (81%).
Phase mix: 65 late (III/IV) vs 114 early (I/II) (early-phase heavy).
Top condition: Glycogen Storage Disease Type II (GSD-II) (5 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Genzyme, a Sanofi Company: open-pipeline peers nationwide
Peers matched on 196 registered trials and 2% open enrollment, not the therapeutic-area sidebar.
Genzyme, a Sanofi Company sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 196 trials (± recruiting share)
- Hospital for Special Surgery, New York · 194 trials · 18% recruiting
- Vertex Pharmaceuticals Incorporated · 191 trials · 10% recruiting
- National Center for Complementary and Integrative Health (NCCIH) · 203 trials · 3% recruiting
- The University of Texas Medical Branch, Galveston · 203 trials · 14% recruiting
Sponsors near 2% open enrollment (± trial volume)
- Cynosure · 2% recruiting · 49 trials
- Carelon Research · 2% recruiting · 50 trials
- Sun Pharmaceutical Industries · 2% recruiting · 48 trials
- Sanofi Pasteur, a Sanofi Company · 2% recruiting · 153 trials
Related
What to do with this Genzyme, a Sanofi Company page
196 registered trials is a research-attention snapshot, not an endorsement of Genzyme, a Sanofi Company or any single study.
- 4 of Genzyme, a Sanofi Company's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Glycogen Storage Disease Type II (GSD-II) is the condition Genzyme, a Sanofi Company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Glycogen Storage Disease Type II (GSD-II) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Genzyme, a Sanofi Company pipeline card: 196 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.